FDA Advisory Committee March 6, 2003

Jun 27, 2013

1.45k likes | 1.66k Views

An Unmet Medical Need. Prevention of Chemotherapy-Induced Nausea and Vomiting. Over one million cancer patients receive chemotherapy each year20% highly emetogenic chemotherapy (HEC)Chemotherapy-induced nausea and vomiting (CINV)Among the most distressing side effects of chemotherapyDisrupt pati

Share Presentation

Embed Code

Link

ull

Download Presentation

FDA Advisory Committee March 6, 2003

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

Colorectal Cancer Screening and Surveillance FDA Advisory Committee March, 2002

Colorectal Cancer Screening and Surveillance FDA Advisory Committee March, 2002 David Lieberman MD Chief, Division of Gastroenterology Oregon Health Sciences University Preventing Cancer Normal Colon Advanced Adenoma Cancer Colon Cancer Prevention MD Colon Cancer Detection

713 views • 36 slides

Preparation for FDA Advisory Committee Meetings

Preparation for FDA Advisory Committee Meetings. Robert M. Kirsch, RAC Vice President, Regulatory Affairs TolerRx Inc. Cambridge, MA. Agenda. “Standard” FDA Meetings Part of Everyday Life for Regulatory Affairs Advisory Committee Meetings

476 views • 18 slides

FDA Oncologic Drugs Advisory Committee Pediatric Oncology Subcommittee

FDA Oncologic Drugs Advisory Committee Pediatric Oncology Subcommittee. Endpoints for New Drugs to Treat Pediatric Brain Tumors 6 December 2006. Report on. Public Workshop on Brain Tumor Clinical Trials Endpoints. 20 January 2006. Sponsored by FDA – AACR – ASCO . Larry E. Kun, MD

644 views • 37 slides

FDA Medical Imaging Drugs Advisory Committee

FDA Medical Imaging Drugs Advisory Committee. July 10, 2000 BLA 99-1407 LeuTech ® Palatin Technologies, Inc. CP000.02. CP001.01. Palatin Presenters. Charles Putnam Chief Operating Officer Palatin Technologies, Inc.

1.25k views • 92 slides

Arthritis Advisory Committee March 5, 2003

Arthritis Advisory Committee March 5, 2003. Lee S. Simon, MD Division Director Analgesic, Anti-inflammatory, Ophthalmologic Drug Products HFD-550/CDER/FDA. Agenda. Regulatory history of Arava in the context of therapy for Rheumatoid arthritis

645 views • 39 slides

FDA Anesthetic & Life Support Drugs Advisory Committee Sept. 10, 2003

FDA Anesthetic & Life Support Drugs Advisory Committee Sept. 10, 2003. Art Van Zee,MD St. Charles Clinic St. Charles, Va. Susstained-release hydromorphone (Palladone) --Risks vs. benefits discussion. Benefits Review sustained release opioids vs. IR opioids.

379 views • 22 slides

Recombinant DNA Advisory Committee September 11, 2003

rAAV-TNFR:Fc Gene Therapy for Rheumatoid Arthritis Protocol 13E04. Recombinant DNA Advisory Committee September 11, 2003. Philip Mease, MD Seattle Rheumatology Associates Director, Swedish Hospital Medical Center Division of Rheumatology Clinical Research Clinical Professor

383 views • 21 slides

Mailers Technical Advisory Committee (MTAC) August 6, 2003

Mailers Technical Advisory Committee (MTAC) August 6, 2003. Automated Package Processing System (APPS). Purpose of APPS Video of APPS in operation Performance Specifications Enhancement to Presort labels Questions/Answers. Purpose of APPS Deployment:

242 views • 5 slides

FDA Advisory Committee Pharmaceutical Sciences November 29, 2001

Individual Bioequivalence: Strengths and Weaknesses of the Current Approach: View from the Generic Pharmaceutical Association by MDS Pharma Services. Mario Tanguay, BPharm, PhD Associate Director, Pharmacokinetics. FDA Advisory Committee Pharmaceutical Sciences November 29, 2001.

254 views • 7 slides

Development of Drugs for Resistant Organisms Presentation to FDA Anti-Infective Drugs Advisory Committee March 5, 2003

Development of Drugs for Resistant Pathogens Characteristics to Justify Development. Microbiological SuperiorityInhibit resistant organismsPharmacological AdvantageFrequency of dosingEase of administrationSafety Advantage. Development of Drugs for Resistant Pathogens Preclinical IND Criteria.

443 views • 24 slides

FDA Anti-Infective Drugs Advisory Committee, October 2003

Diabetic foot infection: what remains to be discovered?. Dr. Tony Berendt, BM, BCh, FRCP Bone Infection Unit, Oxford. FDA Anti-Infective Drugs Advisory Committee, October 2003. Take home messages. Despite considerable advances, there is much we do not know about diabetic foot infection

858 views • 40 slides

FDA Advisory Panel March 5, 2002

Medtronic InSync ® ICD Cardiac Resynchronization System. FDA Advisory Panel March 5, 2002. Agenda. Introduction and Background . William T. Abraham, MD. Introduction.

1.12k views • 95 slides

CHIRON Submission To FDA TSE Advisory Committee Meeting

CHIRON Submission To FDA TSE Advisory Committee Meeting. 19 September 2006 Gaithersburg, MD David Peretz M.Sc., D.Sc. Senior Scientist. Presentation Outline. Review vCJD assay development progress Review assay performance data Review proposed validation process.

258 views • 11 slides

Rectal Microbicide Development FDA Antiviral Advisory Committee 20 th August, 2003

Rectal Microbicide Development FDA Antiviral Advisory Committee 20 th August, 2003. Ian McGowan M.D., Ph.D. Center for HIV & Digestive Diseases at David Geffen School of Medicine, UCLA. Three Questions. Why develop rectal microbicides?

211 views • 9 slides

FDA Advisory Committee Meeting

FDA Advisory Committee Meeting. Transmissible Spongiform Encephalopathies October 14, 2004. Performance of the Enfer TSE Test with Front End Automation. Steve Figard, Ph.D. Senior Scientist Abbott Diagnostics And a Host of Others…. Overview. Brief Overview of the Enfer TSE Assay

262 views • 13 slides

FDA Endocrine and Metabolic Drugs Advisory Committee October 7, 2003

FDA Endocrine and Metabolic Drugs Advisory Committee October 7, 2003. Joseph S. Camardo, M.D. Senior Vice President Clinical Research. Agenda. Introduction and Overview: Use of estrogen/progestin for osteoporosis The clinical data for estrogen/progestin The WHI data and clinical practice

489 views • 36 slides

FDA Advisory Committee for Pharmaceutical Science—March 13, 2003

FDA Advisory Committee for Pharmaceutical Science—March 13, 2003. Carlos R. Hamilton, Jr. MD, FACE American Association of Clinical Endocrinologists—Vice President The University of Texas Health Science Center—Houston, Executive Vice-President for Clinical Affairs .

200 views • 7 slides

FDA Advisory Committee for Lotronex

FDA Advisory Committee for Lotronex. Jeffrey D. Roberts, B.Sc. President & Founder Irritable Bowel Syndrome Self Help Group, Irritable Bowel Syndrome Association, Coordinator Lotronex Action Group jeffrey.roberts@ibsgroup.org http://www.ibsgroup.org. Side Effects while taking Lotronex.

160 views • 5 slides

Peginterferon 2a/Ribavirin FDA Antiviral Drugs Advisory Committee

Peginterferon 2a/Ribavirin FDA Antiviral Drugs Advisory Committee. Brian Murphy, MD, MPH, MS InterMune Submitted November 12, 2002 for Presentation November 14, 2002. Disclosure. Presently serve as Vice-President Corporate Development/Hepatology at InterMune

416 views • 13 slides

FDA ADVISORY COMMITTEES

FDA ADVISORY COMMITTEES. Mary A Foulkes, Ph.D. Office of Biostatistics and Epidemiology Center for Biologics Evaluation and Research, FDA. FDA/Industry workshop Bethesda, MD September 19, 2003. CDER Cardio-Renal Drugs AntiInfective Drugs Antiviral Drugs Oncologic Drugs CBER

329 views • 13 slides

FDA Advisory Committee January 13, 2003

FDA Advisory Committee January 13, 2003. Genzyme Marketing Application STN 103979 / 0 Recombinant human  -Galactosidase For Treatment of Fabry Disease. Agalsidase beta: Proposed indication and dose. Proposed indication: “..indicated for use as a long-term enzyme replacement..”

788 views • 63 slides

FDA Advisory Committee Training

FDA Advisory Committee Training. An Industry Representative Perspective Alison Lawton Sr. VP Regulatory Affairs Genzyme Corporation. Background to Industry Representative. Introduced in FDA Modernization Act Non-voting member, non–SGE Financial interest disclosure Conflict of interest?

187 views • 5 slides

More Related

FDA Advisory Committee March 6, 2003

FDA Advisory Committee March 6, 2003

Presentation Transcript

Colorectal Cancer Screening and Surveillance FDA Advisory Committee March, 2002

Preparation for FDA Advisory Committee Meetings

FDA Oncologic Drugs Advisory Committee Pediatric Oncology Subcommittee

FDA Medical Imaging Drugs Advisory Committee

Arthritis Advisory Committee March 5, 2003

FDA Anesthetic &amp; Life Support Drugs Advisory Committee Sept. 10, 2003

Recombinant DNA Advisory Committee September 11, 2003

Mailers Technical Advisory Committee (MTAC) August 6, 2003

FDA Advisory Committee Pharmaceutical Sciences November 29, 2001

Development of Drugs for Resistant Organisms Presentation to FDA Anti-Infective Drugs Advisory Committee March 5, 2003

FDA Anti-Infective Drugs Advisory Committee, October 2003

FDA Advisory Panel March 5, 2002

CHIRON Submission To FDA TSE Advisory Committee Meeting

Rectal Microbicide Development FDA Antiviral Advisory Committee 20 th August, 2003

FDA Advisory Committee Meeting

FDA Endocrine and Metabolic Drugs Advisory Committee October 7, 2003

FDA Advisory Committee for Pharmaceutical Science—March 13, 2003

FDA Advisory Committee for Lotronex

Peginterferon 2a/Ribavirin FDA Antiviral Drugs Advisory Committee

FDA ADVISORY COMMITTEES

FDA Advisory Committee January 13, 2003

FDA Advisory Committee Training

FDA Anesthetic & Life Support Drugs Advisory Committee Sept. 10, 2003